Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FM8HT
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on September 5, 2025, is scheduled for completion by September 26, 2025, with performance to take place at the vendor's Park Ridge facility. The award carries no set-aside designation, allowing the company to compete on an unrestricted basis despite its small business status.
This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering specialized medications including biologics, auto-injectors, and branded pharmaceutical products to military health systems. The Xolair auto-injector, used for treating moderate-to-severe allergic asthma and chronic idiopathic urticaria, represents one of many critical pharmaceutical products the contractor supplies to support military healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FM8HT?
SPE2DB25FM8HT was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 5, 2025.
How much is contract SPE2DB25FM8HT worth?
The government has obligated $10,273 on SPE2DB25FM8HT.
Is contract SPE2DB25FM8HT an order under another contract?
Yes. SPE2DB25FM8HT is a delivery order under SPE2DB22D9151, an indefinite delivery contract.
Was contract SPE2DB25FM8HT competed?
The extent of competition for SPE2DB25FM8HT was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award